Skip to content

A prospective study of the gene polymorphism on the effect of strong opioid therapy on cancer pain by genomic technology

A prospective study of the gene polymorphism on the effect of strong opioid therapy on cancer pain by genomic technology

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000033576
Enrollment
Unknown
Registered
2020-06-06
Start date
2018-03-05
Completion date
Unknown
Last updated
2020-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer pain

Interventions

Sponsors

cancer center, Union hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 88 Years

Inclusion criteria

Inclusion criteria: (1) aged > 18 years old; (2) patients who were diagnosed as malignant tumor by histology or cytology examination; (3) patients had symptoms of cancer pain and received regular treatment with strong opioids; (4) patients signed the informed consent voluntarily.

Exclusion criteria

Exclusion criteria: (1) patients with poor compliance with analgesic therapy; (2) the purpose of using strong opioid drugs is not to treat cancer pain; (3) cases that the researchers thought it was not suitable for patients.

Design outcomes

Primary

MeasureTime frame
Pain score;The dose of opioids;Gene polymorphism;Adverse drug reaction;Types of adverse drug reactions;

Countries

China

Contacts

Public ContactJianli Hu

cancer center, Union hospital, Tongji Medical College, Huazhong University of Science and Technology

jl5199@126.com+86 13871268129

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026